Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $43.648 million which missed the analyst consensus estimate of $49.450 million by 11.73 percent. This is a 22.58 percent decrease over sales of $56.376 million the same period last year.